• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • Highlights of India’s first Biotech startup Expo
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid
  • Moderna and Pfizer: Lawsuits and Charitable Giving
  • European Commission Approves Two GM Crops for Food and Feed
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

    January 23, 2022

    Interview – Dr Heera Lal: How an IAS officer using Biotech approaches to transform Indian villages into “Organic Villages”

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Articles»Race against COVID19 treatment

Race against COVID19 treatment

0
By Biotech Express on April 19, 2020 Articles, SARS- CoV2 & COVID-19 Updates

by Biotech Express Bureau | Updated on April 20, 2020

There is no cure (or vaccine) against COVID19; Doctors can only relieve the symptoms. Since it is a new pathogen the chances of making a candidate vaccine very soon are very low, yet world’s scientists are working rigorously to find one. The biotech industry, both by pharmaceutical companies and research organisations across the world are working on the development of novel coronavirus vaccines and possible treatment.
But to kill the virus a chemical or biological entity is required which takes time for discovery, approval and gain trust.

The most effective agent for any viral disease is vaccine. Vaccine attenuates the virus and also helps our immune system to destroy and recognize the virus by making antibodies.

According to a post update of Livemint.com on 16th April, nearly 70 ‘vaccine candidates’ are being tested and at least three have moved to the human clinical trial stage, but a vaccine for the novel coronavirus is unlikely to be ready for mass use before 2021.

The pioneer research from India seeking for vaccine candidate came after Scientists, led by Shailendra K. Saxena, sequenced the genes that encode the spike (S) proteins in the outer layer of two strains of coronaviruses isolated from the seafood market of Wuhan, where the novel virus first emerged. They then compared the S protein-coding genes of the novel coronaviruses with those of different strains of SARS-CoV that usually infects bats. The study was published online on 28 March 2020 in Nature.

In a statement of 27th March, the Indian Council for Medical Research said on Friday that India is likely to participate in the solidarity trial of coronavirus vaccine to be conducted by the World Health Organization. “We are likely to start our participation soon in solidarity trial that the World Health Organization is starting.
Earlier we did not do it because our numbers were so small that our contribution would have looked minuscule. The ICMR has asked the Department of Biotechnology (DBT) to undertake vaccine development programme.
On 9th April, two candidate vaccines for COVID-19 have entered the first phase of human clinical trials and another 60 candidate vaccines were in pre-clinical studies, the World Health Organisation (WHO) confirmed.

Vaccine Candidates
The most recent vaccine candidate jointly developed by CanSino Biological Inc and Beijing Institute of Biotechnology uses the non-replicating viral vector as the platform, same as the non-corona candidates like Ebola, to develop a vaccine with a ‘Adenovirus Type 5’ candidate.

US drugmaker Gilead is racing against time with its anti-viral drug Remdesivir. This anti-viral drug is undergoing large trials in China and could be a front runner in coronavirus treatments. According to the company, the drug showed good results in animal testing against MERS and SARS, both of which are also types of coronaviruses. This experimental drug was also been tested against Ebola, however, despite success in animal testing, the drug did not fare too well in humans. The drug is yet not approved to treat any disease, but the company is hoping it could be an effective treatment against Coronavirus.

Another US biopharma company Altimmune is working on an intranasal coronavirus vaccine, which is being developed based on a vaccine technology platform similar to NasoVAX, the influenza vaccine developed by Altimmune. Animal testing will begin shortly.

mRNA-1273 vaccine by Moderna and Vaccine Research Center entered in phase one clinical trials in April.
China’s National Medical Products Administration has approved Favilavir, an anti-viral drug as a treatment against coronavirus. The drug is being touted as the first approved coronavirus drug. While clinical trials are still ongoing in Shenzhen, Guangdong province, results of clinical trials involving 70 patients reportedly showed treatment efficacy with very little side effects.

Korean drugmaker Ilyang Pharma has claimed that its Leukemia drug Supect is found effective against coronavirus. However, it is still to be approved by drug authorities in the country.

Indian drug regulator has approved “restricted use” of combination Liponavir and Ritonavir. This was used by doctors in Sawai Man Singh (SMS) Hospital who claim to have successfully cured Italian COVID-19 patients using a combination of these drugs with swine flu and malaria drugs. Experts said a lot more clinical trials are needed to establish replicability of this treatment.Some Indian firms taking the lead are Serum Institute of India and Zydus Cadila who have disclosed their candidates for coronavirus vaccine.

In India Adar C. Poonawalla, CEO of Pune-based Serum Institute of India(SII), the world’s largest vaccine manufacturer, announced that SII has collaborated with two American companies to develop a Make in India Covid-19 vaccine.

More recently, plasma therapy has been used in the treatment of diseases like SARS in 2003, which was also caused by a coronavirus, as well as MERS in 2012.The therapy is the Convalescent Plasma Therapy. Chances of treating coronavirus patients with plasma therapy are looking up, with the Indian Council of Medical Research (ICMR) hoping to begin clinical trials within the next two weeks. Several states, including Kerala, Maharashtra, Tamil Nadu and Delhi have sought permission from the Centre to conduct plasma therapy to treat coronavirus patients.

An international effort, ‘The coalition of Epidemic Preparedness Innovations’ (CEPI), a global collaboration between public, private, philanthropic, and civil society organisations to develop vaccines for infectious disease epidemics, is currently supporting developmental work on four vaccine candidates.Research organisations such as the National Institutes of Health (NIH), US and Indian Council of Medical Research are also developing a vaccine for the coronavirus.

References:
1. https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf
2.https://indiabioscience.org/columns/general-science/covid-19-vaccine-development-and-therapeutic-strategies
3.https://www.statnews.com/2020/04/16/early-peek-at-data-on-gilead-coronavirus-drug-suggests-patients-are-responding-to-treatment/
4.https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/
5.Study uncovers routes to vaccine for novel Coronavirus doi:10.1038/nindia.2020.52 Published online 28 March 2020
6.https://www.livemint.com/news/india/covid-19-six-indian-companies-working-on-coronavirus-vaccine-11587016987400.html

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Researchers who jumped into the field from distant disciplines published lower impact work, study finds

Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid

No Vaccine Mandates after supreme court order, next compensation to AEFI survivors from COVID Vaccine makers possible?

Leave A Reply Cancel Reply

Current Issue – May 2022

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • Highlights of India’s first Biotech startup Expo June 13, 2022
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity June 6, 2022
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds May 30, 2022
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft May 26, 2022
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak May 25, 2022
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid May 25, 2022
  • Moderna and Pfizer: Lawsuits and Charitable Giving May 25, 2022
  • European Commission Approves Two GM Crops for Food and Feed May 25, 2022
  • Ayush Ministry, DBT sign MoU for cooperation on evidence-based biotech interventions in Ayush sector May 24, 2022
  • CCI, India merger approved absorption of Covidshield Technologies into Biocon Biologics May 20, 2022
  • No Vaccine Mandates after supreme court order, next compensation to AEFI survivors from COVID Vaccine makers possible? May 19, 2022
  • Industry lobbying on WHO overshadowing public health policy, researchers suggest May 18, 2022
  • Letter: Public Health Bill to be presented in the Monsoon session 2022 is Illegal, Unconstitutional and Arbitrary: Dr Maya Valecha May 15, 2022
  • Paid publishing in science has killed peer review system, says CSIR’s ex-chief Shekhar Mande May 15, 2022
  • Bill Gates tests positive for COVID-19 even after many booster doses, mocked on twitter May 10, 2022
  • Another Ivermectin COVID-19 paper retracted May 8, 2022
  • COVID-19 spike protein paper retracted May 7, 2022
  • Killer Music? Can sound make a clot in a boy who died while dancing or it is related to COVID vaccination May 7, 2022
  • Clotting Risks Cause FDA to Restrict Use of J&J COVID Vaccine May 6, 2022
  • Department of Pharmaceuticals releases “Common Guidelines on Pharmaceutical Innovation and Entrepreneurship” for academic institutions May 6, 2022
  • No medical care for 45% of recorded deaths in 2020, highest ever in India: New data May 6, 2022
  • Indian opposition seeks higher compensation for COVID deaths after damning WHO report May 6, 2022
  • Redcliffe Lifetech raises $61 million in Series B funding May 6, 2022
  • Engineers Create an Enzyme That Breaks Down Plastic Waste in Hours, Not Decades May 5, 2022
  • Eris Lifesciences acquires 100% stake in Oaknet Healthcare for Rs 650 cr May 5, 2022
  • The Union Government has Lied to the Supreme Court in COVID Vaccines Case? May 5, 2022
  • COVID-19- vitamin D paper from India retracted by Springer Nature journal May 4, 2022
  • IISc develops 3D printed gloves for rehabilitating stroke patients May 4, 2022
  • A new wearable technology — for plants May 4, 2022
  • Sanofi India names Rodolfo Hrosz managing director effective June 1 May 4, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.